Advertisement

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Peter Clark, MA, MD, FRCP: A Payer Perspective

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Sep
09
Today In Oncology
ELEVATE Trial Shows Disease-Free Survival Benefit With Adjuvant Ensartinib in ALK-Positive NSCLC
Prostate Cancer Higher Saturated Fat Intake May Be Linked to Worse Outcomes
Duane Mitchell Named Director of the UF Health Cancer Institute
Long-Course Chemoradiotherapy Shows Early Organ Preservation Advantage in Rectal Cancer
FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo